Lifeboat Foundation

Most people carry the fungus Candida albicans on their bodies without it causing many problems. However, a systemic infection with this fungus is dangerous and difficult to treat. Few antimicrobials are effective, and drug resistance is increasing. An international group of scientists, including Albert Guskov, associate professor at the University of Groningen, have used single-particle cryogenic electron microscopy to determine the structure of the fungal ribosome. Their results, which were published in Science Advances on 25 May, reveal a potential target for new drugs.

Candida albicans usually causes no problems, or just an itchy skin infection that is easily treated. However, in rare cases, it may cause systemic infections that can be fatal. Existing antifungal drugs cause a lot of side effects and are expensive. Furthermore, C. albicans is becoming more drug-resistant, so there is a real need for new drug targets. “We noted that no antifungal drugs are targeting protein synthesis, while half of the antibacterial drugs interfere with this system,” says Guskov. A reason for this is that fungal ribosomes, the cellular machineries that translate the genetic code into proteins, are very similar in humans and fungi. “So, you would need a very selective drug to avoid killing our own cells.”

Repression of the G protein-coupled chemokine receptor CCR5 enhances MAPK/CREB signaling, long-term potentiation, somatosensory cortical plasticity, and learning and memory, while CCR5 over-activation by viral proteins may contribute to HIV-associated cognitive deficits.

In a paper appearing in Nature today, an international group of scientists report a new way to kill hard-to-treat cancers. These tumors resist current immunotherapies, including those using Nobel Prize-winning checkpoint-blocking antibodies.

The approach exploits Z-DNA. Rather than twisting to the right like B-DNA, Z-DNA has a left-handed twist. One role for Z-DNA is to regulate the immune response to viruses. The response involves AADR1 and ZBP1, two proteins that specifically recognize Z-DNA. They do so through a Zα domain that binds to the Z-DNA structure with high affinity.

The Zα domain was originally discovered by Dr. Alan Herbert of InsideOutBio, a communicating author on the paper. The ADAR1 Zα domain turns off the autoimmune response, while the other ZBP1 Zα turns on pathways that kill virally infected cells, as previously shown by Dr. Sid Balachandran, the other communicating author on the paper. The interactions between ADAR1 and ZBP1 determine whether a tumor cell lives or dies.

𝙏𝙝𝙚 𝙘𝙤𝙣𝙙𝙞𝙩𝙞𝙤𝙣𝙨 𝙘𝙖𝙣 𝙖𝙡𝙡 𝙖𝙛𝙛𝙚𝙘𝙩 𝙩𝙝𝙚 𝙗𝙧𝙖𝙞𝙣, 𝙙𝙖𝙢𝙖𝙜𝙞𝙣𝙜 𝙗𝙡𝙤𝙤𝙙 𝙫𝙚𝙨𝙨𝙚𝙡𝙨 𝙖𝙣𝙙 𝙡𝙚𝙖𝙙𝙞𝙣𝙜 𝙩𝙤 𝙨𝙩𝙧𝙤𝙠𝙚𝙨. 𝘽𝙪𝙩 𝙩𝙝𝙚 𝙘𝙤𝙣𝙣𝙚𝙘𝙩𝙞𝙤𝙣 𝙗𝙚𝙩𝙬𝙚𝙚𝙣 𝙫𝙖𝙨𝙘𝙪𝙡𝙖𝙧 𝙙𝙞𝙨𝙚𝙖𝙨𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙗𝙧𝙖𝙞𝙣 𝙖𝙣𝙙 𝘼𝙡𝙯𝙝𝙚𝙞𝙢𝙚𝙧’𝙨 𝙝𝙖𝙨 𝙧𝙚𝙢𝙖𝙞𝙣𝙚𝙙 𝙪𝙣𝙚𝙭𝙥𝙡𝙖𝙞𝙣𝙚𝙙 𝙙𝙚𝙨𝙥𝙞𝙩𝙚 𝙩𝙝𝙚 𝙞𝙣𝙩𝙚𝙣𝙨𝙚 𝙚𝙛𝙛𝙤𝙧𝙩𝙨 𝙤𝙛 … See more.

The Neuro-Network.

𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐦𝐚𝐲 𝐡𝐚𝐯𝐞 𝐟𝐨𝐮𝐧𝐝 𝐭𝐡𝐞 𝐦𝐢𝐬𝐬𝐢𝐧𝐠 𝐥𝐢𝐧𝐤 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐚𝐧𝐝 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐝𝐢𝐬𝐞𝐚𝐬𝐞

Continue reading “Researchers may have found the missing link between Alzheimer’s and vascular disease” »

An experimental cancer-killing virus has been administered to a human patient for the first time, with hopes the testing will ultimately reveal evidence of a new means of successfully fighting cancer tumors in people’s bodies.

The drug candidate, called CF33-hNIS (aka Vaxinia), is what’s called an oncolytic virus, a genetically modified virus designed to selectively infect and kill cancer cells while sparing healthy ones.

In the case of CF33-hNIS, the modified pox virus works by entering cells and duplicating itself. Eventually, the infected cell bursts, releasing thousands of new virus particles that act as antigens, stimulating the immune system to attack nearby cancer cells.

Noted fund manager and Ark Invest founder Cathie Wood on Saturday suggested that Artificial General Intelligence (AGI) will likely give a strong lift to economic growth.

The fund manager is of the view that a breakthrough in AGI will lead to the acceleration of GDP within the next six to 12 years. The analyst estimates that GDP growth will increase from the 3–5% year-over-year rate currently to 30–50% per year. New DNA will win,’ she added.

Cultivated meat company to bring tiger and zebra meat to your dinner plates this year!

Hey it’s Han from WrySci-HX going through the recent announcement that Primeval Foods will hold tasting events for lion, tiger and zebra meat in 2022. No animals harmed in the process! More below ↓↓↓

Continue reading “Bold Biotech Startup Set to Bring TIGER and ZEBRA Meat to Your Dinner Plates This Year” »